A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
Biopharmaceutical company Idenix has cited the “profound consequences for genus claims” in attacking a federal court ruling to affirm a decision made in a patent dispute with Gilead Sciences.
Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.
Haseltine Lake Kempner has added Jo Deas as a partner to its chemistry and life sciences team, effective January 20.
In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.
A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.
Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
German biotech Jennewein has accused Nestlé Nutrition of infringing patents covering a process of purifying human milk oligosaccharides to make its infant formula.